Physician profile
Hao Meng
NPI 1508288168
$2,632.95
in general payments reported to CMS, 2019-2025
29 companies · $465 in 2025
The $465 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $523 · 2022: $474 · 2023: $508 · 2024: $662 · 2025: $465.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,635.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,635.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $347.73 | 2021-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $295.35 | 2021-2025 | |
| Heartflow, INC. | $241.72 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $214.05 | 2021-2025 | Jardiance |
| Irhythm Technologies, INC. | $211.27 | 2021-2024 | Zio Xt Patch, Zio Monitor |
| Astrazeneca Pharmaceuticals LP | $207.23 | 2021-2025 | Brilinta, Wainua, Farxiga |
| Esperion Therapeutics, INC. | $121.44 | 2021-2025 | Nexletol |
| Merck Sharp & Dohme LLC | $105.38 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $79.84 | 2022-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $77.37 | 2022-2023 | |
| Abiomed | $74.51 | 2024-2025 | Impella |
| Abbott Laboratories | $74.38 | 2021-2024 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Alnylam Pharmaceuticals INC. | $74.17 | 2023-2025 | Onpattro |
| Kiniksa Pharmaceuticals International, Plc | $66.80 | 2024 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $66.19 | 2021-2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $54.47 | 2021-2025 | Lifevest |
| Scpharmaceuticals INC. | $43.95 | 2023-2025 | |
| Pfizer INC. | $42.97 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $39.45 | 2021-2022 | |
| Amarin Pharma, INC. | $32.34 | 2021-2022 | |
| Philips North America LLC | $30.91 | 2025 | Extended Holter |
| Actelion Pharmaceuticals US, INC. | $22.33 | 2023 | Opsumit |
| Vifor Pharma, INC. | $21.75 | 2022 | |
| Daiichi Sankyo INC. | $20.99 | 2023 | Injectafer |
| Boston Scientific Corporation | $15.54 | 2023 | Watchman Access System |
| Novo Nordisk INC | $14.44 | 2021 | |
| Amryt Pharma Holdings LTD | $13.73 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.55 | 2021 | |
| Cvrx, INC. | $10.10 | 2023 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hao Meng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.